



12 April 2022

## Annual General Meeting

**Creso Pharma Limited (ASX:CPH)** ('Creso Pharma' or 'the Company') advises that, in accordance with ASX Listing Rule 3.13.1, it anticipates that it will hold its next Annual General Meeting ("AGM") on 31 May 2022.

In addition, the closing date for the receipt of nominations from persons wishing to be considered for election as a director is 21 April 2022. Any nominations must be received in writing no later than 5.00pm (AEST) on 21 April 2022 at the Company's registered office.

Shareholders will be advised of further details regarding the AGM including the time of the AGM in a separate Notice of Meeting, which will be provided to shareholders in late-April 2022. The Notice of Meeting will also be available on the ASX Company Announcements Platform and the Company's website at [www.cresopharma.com](http://www.cresopharma.com).

**-Ends-**

### Authority and Contact Details

This announcement has been authorised for release by the Disclosure Committee of the Board of Creso Pharma Limited.

For further information, please contact:

#### Investor Enquiries

Creso Pharma Limited  
E: [info@cresopharma.com](mailto:info@cresopharma.com)  
P: +61 (0) 497 571 532

### About Creso Pharma

Creso Pharma Limited (ASX:CPH) brings the best of cannabis to better the lives of people and animals. It brings pharmaceutical expertise and methodological rigor to the cannabis world and strives for the highest quality in its products. It develops cannabis and hemp derived therapeutic, nutraceutical, and life style products with wide patient and consumer reach for human and animal health.

Creso Pharma uses GMP (Good Manufacturing Practice) development and manufacturing standards for its products as a reference of quality excellence with initial product registrations in Switzerland. It has worldwide rights for a number of unique and proprietary innovative delivery technologies which enhance the bioavailability and absorption of cannabinoids. To learn more please visit: [www.cresopharma.com](http://www.cresopharma.com)

### Creso Pharma offices:

#### Australia

Suite 5 CPC, 145 Stirling Hwy, Nedlands, WA, 6009

**Switzerland**

Allmendstrasse 11, 6310 Steinhausen, Schweiz

**Canada**

59 Payzant Drive, Windsor, Nova Scotia, B0N 2T0 and 50 Ivey Ln, Windsor, Nova Scotia, B0N 2T0

**Forward Looking statements**

This announcement contains forward-looking statements with respect to Creso and its respective operations, strategy, investments, financial performance and condition. These statements generally can be identified by use of forward-looking words such as "may", "will", "expect", "estimate", "anticipate", "intends", "believe" or "continue" or the negative thereof or similar variations. The actual results and performance of Creso could differ materially from those expressed or implied by such statements. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding future expectations. Some important factors that could cause actual results to differ materially from expectations include, among other things, general economic and market factors, competition and government regulation.

The cautionary statements qualify all forward-looking statements attributable to Creso and persons acting on its behalf. Unless otherwise stated, all forward-looking statements speak only as of the date of this announcement and Creso has no obligation to up-date such statements, except to the extent required by applicable laws.